Increasing plasma lysophosphatidylcholine levels in patients with regular dextran sulfate lipoprotein apheresis

Atherosclerosis Supplements

Volumn 18, Issue , 2015, Pages 170-175

  Graessler, Juergen ^a   Schuhmann, Kai ^b   Shevchenko, Andrej ^b   Kopprasch, Steffi ^a   Ban, Ryan ^a   Bergmann, Sybille ^a   Bornstein, Stefan R ^a   Hohenstein, Bernd ^a   Julius, Ulrich ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS   (Germany)

Author keywords

Dextran sulfate adsorption; Lipidomics; Lipoprotein apheresis; Lysophosphatidylcholines

Indexed keywords

DEXTRAN SULFATE; LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; BIOLOGICAL MARKER;

ADSORPTION; ADULT; AGED; APHERESIS; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; LIPIDOMICS; LIPOPROTEIN APHERESIS; MALE; METABOLITE; PHOSPHOLIPID BLOOD LEVEL; PLASMA; PRIORITY JOURNAL; BLOOD; HYPERLIPOPROTEINEMIAS; MIDDLE AGED; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME; UPREGULATION;

ADULT; AGED; BIOMARKERS; BLOOD COMPONENT REMOVAL; DEXTRAN SULFATE; FEMALE; HUMANS; HYPERLIPOPROTEINEMIAS; LIPOPROTEINS; LYSOPHOSPHATIDYLCHOLINES; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84928887151     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2015.02.026     Document Type: Article

References (24)

1. Jaeger B.R., Richter Y., Nagel D., Heigl F., Vogt A., Roeseler E., et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009, 6:229-239.
2. Julius U., Frind A., Tselmin S., Kopprasch S., Poberschin I., Siegert G. Comparison of different LDL apheresis methods. Expert Rev Cardiovasc Ther 2008, 6:629-639.
3. Julius U., Taseva K., Fischer S., Passauer J., Bornstein S.R. Current situation of lipoprotein apheresis in Saxony. Atheroscler Suppl 2013, 14:51-55.
4. Leebmann J., Roeseler E., Julius U., Heigl F., Spitthoever R., Heutling D., et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013, 128:2567-2576.
5. Kopprasch S., Graessler J., Bornstein S.R., Schwarz P.E., Tselmin S., Frind A., et al. Beyond lowering circulating LDL: apheresis-induced changes of systemic oxidative stress markers by four different techniques. Atheroscler Suppl 2009, 10:34-38.
6. Tselmin S., Schmitz G., Julius U., Bornstein S.R., Barthel A., Graessler J. Acute effects of lipid apheresis on human serum lipidome. Atheroscler Suppl 2009, 10:27-33.
7. Gräßler J., Kopprasch S., Passauer J., Fischer S., Schuhmann K., Bergmann S., et al. Differential effects of lipoprotein apheresis by lipidfiltration or dextran sulfate adsorption on lipidomic profile. Atheroscler Suppl 2013, 14:151-155.
8. Graessler J., Schwudke D., Schwarz P.E., Herzog R., Shevchenko A., Bornstein S.R. Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. PLoS One 2009, 4:e6261.
9. Matyash V., Liebisch G., Kurzchalia T.V., Shevchenko A., Schwudke D. Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J Lipid Res 2008, 49:1137-1146.
10. Schuhmann K., Almeida R., Baumert M., Herzog R., Bornstein S.R., Shevchenko A. Shotgun lipidomics on a LTQ Orbitrap mass spectrometer by successive switching between acquisition polarity modes. J Mass Spectrom 2012, 47:96-104.
11. Schuhmann K., Herzog R., Schwudke D., Metelmann-Strupat W., Bornstein S.R., Shevchenko A. Bottom-up shotgun lipidomics by higher energy collisional dissociation on LTQ Orbitrap mass spectrometers. Anal Chem 2011, 83:5480-5487.
12. Herzog R., Schuhmann K., Schwudke D., Sampaio J.L., Bornstein S.R., Schroeder M., et al. LipidXplorer: a software for consensual cross-platform lipidomics. PLoS One 2011, 7:e29851.
13. Herzog R., Schwudke D., Schuhmann K., Sampaio J.L., Bornstein S.R., Schroeder M., et al. A novel informatics concept for high-throughput shotgun lipidomics based on the molecular fragmentation query language. Genome Biol 2011, 12:R8.
14. Ojala P.J., Hirvonen T.E., Hermansson M., Somerharju P., Parkkinen J. Acyl chain-dependent effect of lysophosphatidylcholine on human neutrophils. J Leukoc Biol 2007, 82:1501-1509.
15. Rabini R.A., Galassi R., Fumelli P., Dousset N., Solera M.L., Valdiguie P., et al. Reduced Na(+)-K(+)-ATPase activity and plasma lysophosphatidylcholine concentrations in diabetic patients. Diabetes 1994, 43:915-919.
16. Croset M., Brossard N., Polette A., Lagarde M. Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. Biochem J 2000, 345(Pt 1):61-67.
17. Sato H., Kato R., Isogai Y., Saka G., Ohtsuki M., Taketomi Y., et al. Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis. J Biol Chem 2008, 283:33483-33497.
18. Rousset X., Vaisman B., Amar M., Sethi A.A., Remaley A.T. Lecithin: cholesterol acyltransferase-from biochemistry to role in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 2009, 16:163-171.
19. Parthasarathy S., Steinbrecher U.P., Barnett J., Witztum J.L., Steinberg D. Essential role of phospholipase A2 activity in endothelial cell-induced modification of low density lipoprotein. Proc Natl Acad Sci USA 1985, 82:3000-3004.
20. Riederer M., Ojala P.J., Hrzenjak A., Graier W.F., Malli R., Tritscher M., et al. Acyl chain-dependent effect of lysophosphatidylcholine on endothelial prostacyclin production. J Lipid Res 2010, 51:2957-2966.
21. Santamarina-Fojo S., Gonzalez-Navarro H., Freeman L., Wagner E., Nong Z. Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol 2004, 24:1750-1754.
22. Gauster M., Rechberger G., Sovic A., Hörl G., Steyrer E., Sattler W., et al. Endothelial lipase releases saturated and unsaturated fatty acids of high density lipoprotein phosphatidylcholine. J Lipid Res 2005, 46:1517-1525.
23. Rao S.P., Riederer M., Lechleitner M., Hermansson M., Desoye G., Hallström S., et al. Acyl chain-dependent effect of lysophosphatidylcholine on endothelium-dependent vasorelaxation. PLoS One 2013, 8:e65155.
24. Schmitz G., Ruebsaamen K. Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis 2010, 208:10-18.